GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ozureprubart   Click here for help

GtoPdb Ligand ID: 14334

Synonyms: JYB1904 | RPT-904 | RPT904
Immunopharmacology Ligand
Compound class: Antibody
Comment: Ozureprubart is a humanized IgG1κ monoclonal antibody against the constant region of the heavy chain of IgE (IGHE). It utilises the same epitope on the target protein as omalizumab and like its predecessor is designed to treat moderate to severe IgE-mediated immune reactions. Ozureprubart was originally developed by Jemincare Pharmaceutical (as JYB1904) and was licensed to Rapt Therapeutics (with code changed to RPT904) in 2025. Rapt was bought by GSK in early 2026. Based on available evidence we suspect that ozureprubart is antibody AB1904Am15 in [2] and patent WO2022007965A1 [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Ozureprubart (RPT905, formerly JYB1904) was advanced to clinical evaluations to determine safety [3] and efficacy as a prophylactic for patients with food allergies, and to treat allergic asthma and chronic spontaneous urticaria. Ozureprubart is proposed as being a "bio-better" of omalizumab as it has an extended half-life (supports an 8-12 week administration cycle) that translates to a stronger and longer reduction in circulating IgE [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05449535 Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects Phase 1 Interventional Jemincare 3
NCT07220811 Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy Phase 2 Interventional RAPT Therapeutics, Inc.
NCT06509334 Trial of JYB1904 in Chronic Spontaneous Urticaria. Phase 2 Interventional Jemincare
NCT06438757 Trial of JYB1904 in Patients With Allergic Asthma Phase 2 Interventional Jemincare